Sarepta shares first results on next-generation Duchenne drug

Sarepta Therapeutics on Monday said an experimental, second-generation therapy for Duchenne muscular dystrophy showed promise in its first clinical trial.
According to Sarepta, early results from the Phase 2 dosing study suggest the therapy, known as SRP-5051, may be more powerful at a lower dose than the company's marketed drug, Exondys 51. Sarepta received approval for Exondys in 2016, despite a dramatic dispute within the Food and Drug Administration.